Brief: Island Pharmaceuticals Says Island Submits Responses To FDA Questions For Isla-101
17/04/2023 02:32
April 17 (Reuters) - Island Pharmaceuticals Ltd
ILA.AX :
* ISLAND SUBMITS RESPONSES TO FDA QUESTIONS FOR ISLA-101
* ISLA-101 BEING REPURPOSED FOR PREVENTION & TREATMENT OF
DENGUE
FEVER AND OTHER MOSQUITO (OR VECTOR) BORNE DISEASES
Source text for Eikon: ID:nASXc7xF79
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic